Muraglitazar
Sponsors
Bristol-Myers Squibb
Conditions
Diabetes MellitusDiabetes Mellitus IIDiabetes Mellitus, Type 2Diabetes, Type 2DyslipidemiaMetabolics Diabetes NosType 2 DiabetesType 2 Diabetes Mellitus
Phase 2
Dose Ranging Study With LT, Monotherapy, PPAR
CompletedNCT00240383
Start: 2002-05-31End: 2006-06-30Target: 1260Updated: 2010-09-14
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
CompletedNCT00245388
Start: 2002-04-30End: 2002-07-31Target: 330Updated: 2012-04-23
Phase 3
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
CompletedNCT00095030
Start: 2004-02-29End: 2006-03-31Target: 1752Updated: 2010-09-14
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
CompletedNCT00094991
Start: 2004-05-31End: 2006-05-31Target: 42Updated: 2010-09-14
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
CompletedNCT00106808
Start: 2005-08-31End: 2006-08-31Target: 1440Updated: 2010-09-14
PPAR - Combination With Metformin
CompletedNCT00162240
Start: 2003-06-30End: 2004-05-31Target: 534Updated: 2012-04-27
PPAR-COMBO With Sulfonylurea
CompletedNCT00162175
Start: 2003-07-31End: 2005-11-30Target: 534Updated: 2010-09-14
A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
CompletedNCT00240370
Start: 2003-10-31Target: 1159Updated: 2010-09-14
A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
CompletedNCT00246987
Start: 2003-06-30End: 2004-04-30Target: 341Updated: 2012-04-27